BCR-ABL positive Leukemia
Identification of Bisindolylmaleimide IX as a potential agent to treat drug-resistant BCR-ABL positive leukemia
... myeloid leukemia (CML) treatment with BCR-ABL inhibitors is often hampered by development of drug ...cells positive for BCR-ABL. BCR-ABL positive cells ...
16
c-MYB is a transcriptional regulator of ESPL1/Separase in BCR-ABL-positive chronic myeloid leukemia
... master regulator [46]. It binds directly near or within 793 genes thereby affecting more than 2300 genes that make up the gene signatures for normal and leukemic stem/pro- genitor cells and myeloid development. Despite ...
9
Characteristics and mutation analysis of Ph-positive leukemia patients with T315I mutation receiving tyrosine kinase inhibitors
... mutated BCR-ABL, including the T315I BCR-ABL mutation; three patients with T315I mutation have achieved clinical responses to doses of MK-0457 that are not associated with adverse ...
8
Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia
... of BCR-ABL tyrosine kinase inhibitors (TKIs) have improved outcomes for patients diagnosed with chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic ...
8
Bcr-abl Silencing by Specific Small-Interference RNA Expression Vector as a Potential Treatment for Chronic Myeloid Leukemia
... the Bcr-abl transcript was observed at 24 hours after transfection may be due to (a) the oligonucleotide degradation occurring under intracellular conditions and (b) a cell division was significantly ...
8
Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells
... both BCR-ABL-dependent and BCR-ABL-independent CML. BCR-ABL-independent activation of the PI3K signaling pathway has also been reported in ABL TKI- resistant CML cell ...
11
Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib
... harboring bcr-abl mutations associated with imatinib resistance (except T315I), and also in patients with a resistance that were independent of bcr-abl ...
9
Subcellular localization of Bcr, Abl, and Bcr Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation
... endogenous Bcr protein, as well as the aberrant p210BCR-ABL and p190BCR-ABL proteins consistently localize to the cytoplasm in both cell lines and fresh ...myelogenous leukemia (CML) cell ...
16
Prognostic Features of BCR ABL Genetic Variations in Acute Lymphoblastic Leukemia
... The first generation of BCR/ABL single fusion FISH probes detected the fu- sion gene with high specificity (false positive rate 5%) but with a low sensitivity. A new generation of FISH probes has ...
11
Molecular signatures of chronic myeloid leukemia stem cells
... of BCR-ABL-transduced bone marrow cells from P-selectin-deficient donors develop more aggres- sive CML, with increased percentages of LSCs and pro- genitors ...
6
Oncogenic kinase fusions: an evolving arena with innovative clinical opportunities
... of BCR-ABL (p210) retroviral-transduced marrow precursors into recipient mice can indeed cause rapidly progressing MPNs, which closely resemble human CML ...of BCR-ABL alone from the knock- in ...
23
Acute lymphoblastic leukemia with e1a3 BCR/ABL fusion protein. A report of two cases
... of BCR-ABL1 fusion gene ...internal positive control in where a 690-bp segment of the ubiqui- tously expressed transcription factor E2A mRNA was ampli- ...a BCR- ABL transcript this band was ...
5
Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy
... of BCR-ABL protein present in these cells ...of BCR- ABL in stem cell antigen 1 (Sca1)-positive cells, the authors generated a murine CML intrinsically resistant to IM ...the ...
15
The Mechanism by which Chronic Myeloid Leukemia Responds to Interferon α Treatment
... Myeloid Leukemia (CML) patients improves its capacity to stimulate T-lymphocyte responses, and decreases the proportion of bcr-abl positive ...of bcr-abl in fresh samples from ...
7
Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells
... in BCR-ABL-positive cells HDACs have been identified as novel targets for the treat- ment of hematologic malignancies, including Ph-positive ...against BCR-ABL-positive ...
9
Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms
... the Bcr-Abl tyrosine kin- ase resulting from the t(9;22) chromosomal translocation is necessary for the transformed phenotype of chronic myelogenous leukemia (CML) ...The Bcr-Abl fusion ...
16
Inhibition of proteasome by bortezomib increase chemosensitivity of bcr/abl positive human k562 chronic myleoid leukemia cells to imatinib
... In this study we evaluated the possible synergy of combination of imatinib and bortezomib. Our data pro- vide that bortezomib enhanced the chemosensitivity of BCR/ABL positive human K562 CML cells to ...
5
Adult acute megakaryoblastic leukemia: rare association with cytopenias of undetermined significance and p210 and p190<em> BCR–ABL</em> transcripts
... were positive for CD34, CD117, CD61 and ...two BCR–ABL transcripts: p210 and p190, transcripts detected by quantitative polymerase chain reaction ...
5
RNA quantification using gold nanoprobes - application to cancer diagnostics
... a positive and negative from as little as 10 ng/ μl of total ...the BCR- ABL fusion product that is of paramount importance in chronic myeloid leukemia, showing the application potential in ...
8
Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib
... p210 positive cells engineered to express muta- tions; activity was demonstrated also in bone marrow cells from normal mice transduced with normal and mutant cells (E255V): treatment with nilotinib prolonged ...
10